Sign in Subscribe
United States. Securities and Exchange Commission

Amgen Inc. Files SEC Form 4 Report

Strategic Insights

— 1 min read

Biotech Week reported on a U.S. Securities and Exchange Commission (SEC) filing by Amgen Inc. (Form 4) on August 11, 2023. The filing, which was posted by a News Reporter from Washington, D.C., pertains to the company's SIC code of 2836, Biological Products, and its headquarters at One Amgen Center Drive in Thousand Oaks, CA.

Key Takeaways:

  • Amgen Inc. is a biopharmaceutical company that filed a SEC Form 4 report on August 11, 2023.
  • The report was submitted by the company as part of its obligation to disclose its ownership and transactions involving equity securities.
  • The SEC Form 4 reports on purchases and sales of equity securities by directors, officers, and owners of more than 10% of the company's outstanding shares.
  • The report provides information on the individual's relationship to the company and their transactions with the company's equity securities.
  • The filing is part of the company's compliance with Section 12 of the Securities Exchange Act of 1934.
  • The SEC file number for this report is 0001127602-23-022410.
  • The contact information for this company is One Amgen Center Drive, Thousand Oaks, CA 91320, and can be reached at (805)447-1000.

Statistics:

  • SIC code for Amgen Inc.: 2836, Biological Products, (No Diagnostic Substances)
  • Number of documents filed with Form 4: 1
  • SEC file number: 0001127602-23-022410
  • Contact information for Amgen Inc.: One Amgen Center Drive, Thousand Oaks, CA 91320, (805)447-1000

Sources:

  • "U.S. Securities and Exchange Commission Filing(date not specified): https://www.sec.gov/Archives/edgar/data/1642156/0001127602-23-022410-index.html
  • "Form 4: Statement of Changes in Beneficial Ownership" (date not specified)

Read more